Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 5, 2011, Pages 512-520

  Widhalm, Georg ^a,b   Krssak, Martin ^a   Minchev, Georgi ^a   Wöhrer, Adelheid ^b   Traub Weidinger, Tatjana ^a   Czech, Thomas ^a   Asenbaum, Susanne ^a   Marosi, Christine ^a   Knosp, Engelbert ^a   Hainfellner, Johannes A ^b   Prayer, Daniela ^a   Wolfsberger, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; METHIONINE C 11; N ACETYLASPARTIC ACID; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL; ADOLESCENT; BRAIN; BRAIN TUMOR; GLIOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ASPARTIC ACID; BRAIN; BRAIN NEOPLASMS; CHOLINE; CREATINE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 79953840340     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.205229     Document Type: Article

References (40)

1. Barker FG 2nd, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997; 80: 936-41. (Pubitemid 27360923)
2. Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998; 49: 436-40. (Pubitemid 28153024)
3. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993; 79: 533-6. (Pubitemid 23289810)
4. Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol 2008; 11: 176-82.
5. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005; 102: 318-27. (Pubitemid 43194083)
6. Gumprecht H, Grosu AL, Souvatsoglou M, et al. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 2007; 68: 19-23. (Pubitemid 46745004)
7. Hatakeyama T, Kawai N, Nishiyama Y, et al. (11)C-methionine (MET) and (18) F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008; 35: 2009-17.
8. Roessler K, Gatterbauer B, Becherer A, et al. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 2007; 50: 273-80.
9. Singhal T, Narayanan TK, Jain V, et al. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008; 10: 1-18.
10. Stadlbauer A, Prante O, Nimsky C, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med 2008; 49: 721-9. (Pubitemid 351717536)
11. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38: 1459-62. (Pubitemid 27386211)
12. Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. Am J Neuroradiol 2007; 28: 455-61. (Pubitemid 46481882)
13. Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006; 104: 238-53.
14. Tanaka Y, Nariai T, Momose T, et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg 2009; 110: 163-72.
15. Ceyssens S, Van LK, de GT, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 2006; 27: 1432-7. (Pubitemid 44260122)
16. Hattingen E, Raab P, Franz K, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008; 50: 759-67.
17. Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002; 20: 343-9.
18. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996; 84: 449-58. (Pubitemid 26062870)
19. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62: 109-19. (Pubitemid 46039402)
20. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006; 238: 958-69. (Pubitemid 43289928)
21. Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001; 49: 823-9. (Pubitemid 32927953)
22. Fayed N, Morales H, Modrego PJ, et al. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate lowgrade from high-grade cerebral gliomas. Acad Radiol 2006; 13: 728-37.
23. Guillevin R, Menuel C, Duffau H, et al. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 2008; 87: 181-7.
24. Jeun SS, Kim MC, Kim BS, et al. Assessment of malignancy in gliomas by 3T 1H MR spectroscopy. Clin Imaging 2005; 29: 10-15.
25. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003; 24: 1989-98. (Pubitemid 37444849)
26. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Am J Neuroradiol 1996; 17: 737-47. (Pubitemid 26124999)
27. Tamiya T, Kinoshita K, Ono Y, et al. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 2000; 42: 333-8. (Pubitemid 30265348)
28. Toyooka M, Kimura H, Uematsu H, et al. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation. Clin Imaging 2008; 32: 251-8. (Pubitemid 351899273)
29. Potzi C, Becherer A, Marosi C, et al. [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 2007; 84: 305-14.
30. Stadlbauer A, Moser E, Gruber S, et al. Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/ magnetic resonance spectroscopy hybrid data set. J Neurosurg 2004; 101: 287-94. (Pubitemid 38971006)
31. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC, 2007.
32. Go KG, Keuter EJ, Kamman RL, et al. Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994; 34: 994-1002. (Pubitemid 24174239)
33. Luyten PR, Marien AJ, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990; 176: 791-9. (Pubitemid 20266774)
34. Go KG, Kamman RL, Mooyaart EL, et al. Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology 1995; 37: 198-206.
35. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg 2007; 106: 660-6. (Pubitemid 46536464)
36. Nelson SJ, Vigneron DB, Dillon WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999; 12: 123-38. (Pubitemid 29258551)
37. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-22. (Pubitemid 28240345)
38. Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C]Lmethionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004; 10: 7163-70. (Pubitemid 39487701)
39. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002; 15: 385-92.
40. Son BC, Kim MC, Choi BG, et al. Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy. Acta Neurochir (Wien) 2001; 143: 45-9.